Research Article
No access
Published Online: 12 January 2016

Insulin Pumps in Type 1 Diabetes with Mental Disorders: Real-Life Clinical Data Indicate Discrepancies to Recommendations

Publication: Diabetes Technology & Therapeutics
Volume 18, Issue Number 1

Abstract

Background: The latest American Association of Clinical Endocrinologists/American College of Endocrinologists consensus statement published in 2014 does not recommend continuous subcutaneous insulin infusion (CSII) in patients with mental health problems. This study investigated the use and discontinuation of CSII in daily routine care of type 1 diabetes (T1D) patients with or without comorbid mental disorders.
Materials and Methods: Insulin-treated T1D patients (n = 48,700) between 5 and 30 years of age (median [interquartile range], 15.6 [12.0–17.7] years) from the German/Austrian diabetes patient follow-up registry (DPV) were studied. A comorbid diagnosis and/or specific treatment of mental disorder was documented in 3,158 (6.5%) patients: attention-deficit hyperactivity disorder (ADHD), n = 1,352; depression, n = 692; eating disorders, n = 395; needle phobia, n = 319; anxiety/obsessive compulsive disorder (OCD), n = 231; and psychosis and/or neuroleptic medication, n = 169. Multivariable logistic regression with age, sex, diabetes duration, and migration background as independent variables was used to compare groups.
Results: After adjustment for confounders, use of CSII was more common in patients with depression (41.5%), anxiety/OCD (41.4%), or needle phobia (75.8%) compared with patients without mental disorders (34.6%) (each P < 0.05). By contrast, psychotic patients (26.2%, P < 0.05) used CSII less often, and patients with ADHD (36.3%) or eating disorders (33.9%) used it with a similar frequency. Compared with patients without mental disorders (5.1%), the rate of CSII discontinuation was higher in patients with ADHD (9.7%), depression (8.2%), or eating disorders (10.0%) (P < 0.05, respectively) but similar in patients with anxiety/OCD (6.0%), psychosis (4.2%), or needle phobia (5.3%).
Conclusions: In routine diabetes care, CSII use and discontinuation vary widely among T1D patients with mental disorders and indicate clear differences from the latest recommendations.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Zenlea IS, Mednick L, Rein J, et al.: Routine behavioral and mental health screening in young children with type 1 diabetes mellitus. Pediatr Diabetes 2014;15:384–388.
2.
Butwicka A, Frisén L, Almqvist C, et al.: Risks of psychiatric disorders and suicide attempts in children and adolescents with type 1 diabetes: a population-based cohort study. Diabetes Care 2015;38:453–459.
3.
Bernstein CM, Stockwell MS, Gallagher MP, et al.: Mental health issues in adolescents and young adults with type 1 diabetes: prevalence and impact on glycemic control. Clin Pediatr (Phila) 2013;52:10–15.
4.
Grunberger G, Abelseth JM, Bailey TS, et al.: Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. Endocr Pract 2014;20:463–489.
5.
Scheuing N, Bartus B, Berger G, et al.: Clinical characteristics and outcome of 467 patients with a clinically recognized eating disorder identified among 52,215 patients with type 1 diabetes: a multicenter German/Austrian study. Diabetes Care 2014;37:1581–1589.
6.
Plener PL, Molz E, Berger G, et al.: Depression, metabolic control, and antidepressant medication in young patients with type 1 diabetes. Pediatr Diabetes 2015;16:58–66.
7.
Galler A, Bollow E, Meusers M, et al.: Comparison of glycaemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian diabetes survey DPV. Diabetes Care 2015;38:1051–1057.
8.
Grant P, Dworakowska D, DeZoysa N, et al.: The impact of anxiety and depression on patients within a large type 1 diabetes insulin pump population. An observational study. Diabetes Metab 2013;39:439–444.
9.
Rotella F, Lamanna C, Dicembrini I, et al.: Psychopathology and continuous subcutaneous insulin infusion in type 1 diabetes. Sci World J 2013;2013:e672729.
10.
Cemeroglu AP, Can A, Davis AT, et al.: Fear of needles in children with type 1 diabetes mellitus on multiple daily injections and continuous subcutaneous insulin infusion. Endocr Pract 2015;21:46–53.
11.
Pinhas-Hamiel O, Graph-Barel C, Boyko V, et al.: Long-term insulin pump treatment in girls with type 1 diabetes and eating disorders—is it feasible? Diabetes Technol Ther 2010;12:873–878.
12.
Wong JC, Dolan LM, Yang TT, et al.: Insulin pump use and glycemic control in adolescents with type 1 diabetes: predictors of change in method of insulin delivery across two years. Pediatr Diabetes 2014 November 10 [Epub ahead of print].
13.
Markowitz JT, Alleyn CA, Phillips R, et al.: Disordered eating behaviors in youth with type 1 diabetes: prospective pilot assessment following initiation of insulin pump therapy. Diabetes Technol Ther 2013;15:428–433.
14.
Hintzpeter B, Klasen F, Schön G, et al.: Mental health care use among children and adolescents in Germany: results of the longitudinal BELLA study. Eur Child Adolesc Psychiatry 2015;24:705–713.
15.
American Diabetes Association: Standards of medical care in diabetes—2015. Diabetes Care 2015;38(Suppl 1):S1–S94.

Information & Authors

Information

Published In

cover image Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
Volume 18Issue Number 1January 2016
Pages: 34 - 38
PubMed: 26451621

History

Published online: 12 January 2016
Published in print: January 2016
Published ahead of print: 9 October 2015

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Nicole Prinz
Institute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, University of Ulm, Ulm, Germany.*
Christina Bächle
Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.*
Marianne Becker
Clinic for Children and Adolescents, Dr. Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany.
Gabriele Berger
Department of Pediatric and Adolescent Medicine, Medical University Vienna, Vienna, Austria.
Angela Galler
Pediatric Endocrinology and Diabetology, University Hospital for Children and Adolescents, Campus Virchow, Charité–University Hospital Berlin, Berlin, Germany.
Holger Haberland
Hospital for Children and Adolescents, Sana Hospital Berlin Lindenhof, Berlin, Germany.
Michael Meusers
Department of Child and Adolescent Psychiatry and Neurology, Community Hospital, Herdecke, Germany.
Joaquina Mirza
Children's Hospital, Hospitals of the City of Cologne, Cologne, Germany.
Paul L. Plener
Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany.
Simone von Sengbusch
Clinic for Child and Adolescent Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Michaela Thienelt
Clinic for Children and Adolescents, St. Vincenz Hospital, Christophorus Clinics, Coesfeld, Germany.
Reinhard W. Holl
Institute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, University of Ulm, Ulm, Germany.*
on behalf of the DPV Initiative

Notes

Parts of the study were presented orally in abstract form at the 40th Annual Conference of the International Society for Pediatric and Adolescent Diabetes, held in Toronto, Ontario, Canada, September 3–6, 2014.
*
This institution is a member of the German Center for Diabetes Research (DZD), funded by the Federal Ministry for Education and Research.
Address correspondence to:Nicole Prinz, PhDInstitute of Epidemiology and Medical BiometryCentral Institute for Biomedical TechnologyUniversity of UlmAlbert-Einstein-Allee 4189081 Ulm,Germany
E-mail: [email protected]

Author Disclosure Statement

S.v.S. reported advisory activity for Medtronic, received speaking fees and reimbursement of travel costs from Bayer Healthcare, Medtronic, Novo Nordisk, and Roche, and obtained three insulin pumps for a research project from Medtronic free of charge. N.P, C.B., M.B., G.B., A.G., H.H., M.M., J.M., P.L.P., M.T., and R.W.H. declare no competing financial interests exist.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top